Capital Investment Advisors’s Taysha Gene Therapies TSHA Stock Holding History

Capital Investment Advisors’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$44.7K	Hold	10,000	–	–	﹤0.01%	747
2025 Q4	$55K	Hold	10,000	–	–	﹤0.01%	733
2025 Q3	$32.7K	Hold	10,000	–	–	﹤0.01%	728
2025 Q2	$23.1K	Hold	10,000	–	–	﹤0.01%	700
2025 Q1	$13.9K	Hold	10,000	–	–	﹤0.01%	678
2024 Q4	$17.3K	Hold	10,000	–	–	﹤0.01%	658
2024 Q3	$20.1K	Hold	10,000	–	–	﹤0.01%	655
2024 Q2	$22.4K	Hold	10,000	–	–	﹤0.01%	636
2024 Q1	$28.7K	Hold	10,000	–	–	﹤0.01%	627
2023 Q4	$17.7K	Hold	10,000	–	–	﹤0.01%	614
2023 Q3	$31.6K	Buy	+10,000	New	+$18.7K	﹤0.01%	595

Other funds holding TSHA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital Investment Advisors's TSHA Position: Q1 2026 in Review

Capital Investment Advisors held its Taysha Gene Therapies (TSHA) position steady in Q1 2026 at 10,000 shares worth $44.7K. The position accounts for ﹤0.01% of the portfolio, ranked #747.

Capital Investment Advisors first reported a position in TSHA in Q3 2023 and has held it in 11 quarters since. The position peaked at $55K in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

Capital Investment Advisors held 10,000 shares of Taysha Gene Therapies worth $44.7K as of Q1 2026.
Capital Investment Advisors left its Taysha Gene Therapies share count unchanged in Q1 2026.
Taysha Gene Therapies made up ﹤0.01% of Capital Investment Advisors's portfolio in Q1 2026, its #747 holding.
Capital Investment Advisors first reported a position in Taysha Gene Therapies in Q3 2023 and has held it in 11 quarters since.
Capital Investment Advisors's Taysha Gene Therapies position peaked at $55K in Q4 2025.
191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Capital Investment Advisors's 13F filing for Q1 2026, filed 16 Apr 2026.